Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Non-Current Liabilities: 2017-2024

Historic Total Non-Current Liabilities for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $56.1 million.

  • Aclaris Therapeutics' Total Non-Current Liabilities rose 6.13% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of $56.1 million for FY2024, which is 64.79% up from last year.
  • Aclaris Therapeutics' Total Non-Current Liabilities amounted to $56.1 million in FY2024, which was up 64.79% from $34.0 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Total Non-Current Liabilities registered a high of $56.1 million during FY2024, and its lowest value of $23.9 million during FY2022.
  • For the 3-year period, Aclaris Therapeutics' Total Non-Current Liabilities averaged around $38.0 million, with its median value being $34.0 million (2023).
  • As far as peak fluctuations go, Aclaris Therapeutics' Total Non-Current Liabilities dropped by 12.39% in 2021, and later spiked by 64.79% in 2024.
  • Aclaris Therapeutics' Total Non-Current Liabilities (Yearly) stood at $29.1 million in 2020, then fell by 12.39% to $25.5 million in 2021, then decreased by 6.26% to $23.9 million in 2022, then surged by 42.52% to $34.0 million in 2023, then spiked by 64.79% to $56.1 million in 2024.